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Abstract
Background: The cyclic nucleotides cyclic adenosine-39,59-monophosphate (cAMP) and cyclic guanosine-39,59-monophos-
phate (cGMP) are important second messengers and are potential biomarkers for Parkinson’s disease (PD), amyotrophic
lateral sclerosis (ALS) and Creutzfeldt-Jakob disease (CJD).
Methodology/Principal Findings: Here, we investigated by liquid chromatography/tandem mass spectrometry (LC-MS/MS)
the cerebrospinal fluid (CSF) concentrations of cAMP and cGMP of 82 patients and evaluated their diagnostic potency as
biomarkers. For comparison with a well-accepted biomarker, we measured tau concentrations in CSF of CJD and control
patients. CJD patients (n=15) had lower cAMP (270%) and cGMP (255%) concentrations in CSF compared with controls
(n=11). There was no difference in PD, PD dementia (PDD) and ALS cases. Receiver operating characteristic (ROC) curve
analyses confirmed cAMP and cGMP as valuable diagnostic markers for CJD indicated by the area under the curve (AUC) of
0.86 (cAMP) and 0.85 (cGMP). We calculated a sensitivity of 100% and specificity of 64% for cAMP and a sensitivity of 67%
and specificity of 100% for cGMP. The combination of both nucleotides increased the sensitivity to 80% and specificity to
91% for the term cAMPxcGMP (AUC 0.92) and to 93% and 100% for the ratio tau/cAMP (AUC 0.99).
Conclusions/Significance: We conclude that the CSF determination of cAMP and cGMP may easily be included in the
diagnosis of CJD and could be helpful in monitoring disease progression as well as in therapy control.
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Introduction
The cyclic nucleotides cyclic adenosine-39,59-monophosphate
(cAMP) and cyclic guanosine-39,59-monophosphate (cGMP) are
important second messengers. Synthesis by adenylate and
guanylate cyclases and degradation by phosphodiesterases (PDEs)
regulate the concentrations of cAMP and cGMP [1].
In the brain, cAMP and cGMP signaling is involved in a
multitude of mechanisms in neurons, astrocytes, oligodendrocytes
and microglia. Examples are signal transduction in synapses,
communication between neurons and glia cells or inflammatory
processes [2,3]. Alterations of these second messengers affect
normal brain function and can be found in several neurological
diseases. Parkinson’s disease (PD) is characterised by the
degeneration of dopaminergic neurons in the substantia nigra.
In a rat model of PD, the destruction of nigral dopaminergic
neurons with the neurotoxin 6-hydroxydopamine (6-OHDA)
resulted in an increase of striatal cAMP and decrease of striatal
cGMP [4,5]. Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disorder characterised by a loss of motor neurons in the
spinal cord, brain stem and cerebral cortex. In a genetic mouse
model of ALS lower concentrations of cGMP in the cerebral
cortex have been reported [6,7]. In Creutzfeldt-Jakob disease
(CJD) a reduced expression of soluble guanylate cyclase b1i n
astrocytes in the white matter [8] has been shown but data on
cGMP concentrations from human brain samples in CJD are
missing.
To date, clinical or even preclinical biomarkers for neurode-
generative diseases such as PD, ALS, CJD are desirable and in the
focus of biomedical research [9,10]. A biomarker as defined by the
National Institutes of Health is ‘‘a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention’’ [11]. Cerebrospinal fluid (CSF) is
currently the preferred central source for biochemical biomarkers
in neurological disorders because CSF is close to the site of the
neuropathology and is routinely taken in specialised centers during
the clinical work-up of patients under the differential diagnosis of a
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CSF with the desired degree of specificity and sensitivity for
clinical diagnosis of PD, PD dementia (PDD) and ALS are still
missing. Usually, post mortem histopathological analysis is
necessary to confirm the diagnosis [9,10,13]. There are some
promising CSF biomarker candidates in PD with a-synuclein as
the most important and also in ALS (e.g. neurofilament heavy
chain or erythropoietin) but they lack sensitivity and specificity
[10,13–17]. In CJD, there are already some CSF markers in use in
combination with other diagnostic tools. More precisely, the
diagnostic criteria of CJD include the increase in CSF concentra-
tions of the 14-3-3 protein [18]. However, this marker cannot be
used in a ‘‘screening’’ situation [19,20]. Other proteins such as tau,
ERK2, ubiquitin or most recently aggregated prion protein (PrP)
have been identified as potential biomarkers but their specificity
has not yet been confirmed [20–23].
The aim of the present study is to investigate cAMP and cGMP
in CSF of PD, PDD, ALS, CJD and control patients. The analysis
of cAMP and cGMP in CSF is carried out with liquid
chromatography coupled to tandem mass spectrometry (LC-
MS/MS). To evaluate the suitability of cAMP and cGMP as
biomarkers we use receiver operating characteristic (ROC) curves
and the Youden index [24] to calculate the cut-off value with the
best combination of sensitivity and specificity for diagnosis.
Materials and Methods
Patients and CSF collection
All patients included in this study attended to the general
outpatient clinic, the outpatient memory clinic, the outpatient
clinic for motoneuron diseases or the surveillance unit for
transmissible spongiform encephalopathies (University of Go ¨ttin-
gen and University of Ulm, Departments of Neurology). The
Ethics Committees of the Universities Go ¨ttingen and Ulm
approved the collection and analysis of CSF samples and
specifically approved this study (Ulm). Samples of CJD patients
were obtained from the surveillance and therapy trail [20,25]. All
patients or their relatives provided written consent to be included
in these studies. CSF was collected by lumbar puncture,
centrifuged and stored at 280uC until analysis. The time between
lumbar puncture and final storage ranged between 6 and 48 h.
Patients with PD or PDD
Table 1 shows the characteristics of the PD and PDD patients.
The clinical diagnosis including the Mini Mental State Examina-
tion (MMSE) and the Hoehn & Yahr score was carried out by
neurologists and neuropsychologists according to the DSM-IV
criteria and the consensus criteria for PD and PDD [26].
Patients with ALS
The group consisted of 14 patients diagnosed with ALS. Table 1
summarises the characteristics of the patients.
Patients with CJD
Table 1 shows the characteristics of the CJD patients. Nine of
the CJD patients were neuropathologically verified as definite CJD
cases. Among them, six patients had two methionine alleles (M/M)
at the PRNP codon 129, one was heterozygous (M/V) and two
patients were homozygous for the valine (V/V) allele. Five of the
definite cases had a positive 14-3-3 immunoblot and one of them
was diagnosed as familial CJD (fCJD). Tau protein exceeded the
proposed cut-off of 1300 pg/mL in all but the fCJD case [20]. The
genotype at PRNP codon 129 of the five neuropathologically-
defined probable CJD cases is unknown except for one (M/M). All
of them had a positive 14-3-3 immunoblot and tau protein in the
CSF above the cut-off. A last case underwent no histopathological
examination but was diagnosed as fCJD.
Control patients
We investigated different control groups for the three
neurodegenerative diseases to account for age differences.
Table 1 shows the characteristics of the groups. The statistical
analysis later on showed no difference in the cAMP and cGMP
concentrations between the three control groups (p=0.70 for
cAMP and p=0.38 for cGMP, Kruskal-Wallis test). The cAMP
and cGMP concentrations did not correlate with age as well.
Control patients for PD and PDD. The control patients
had the following diagnosis: polymyositis (two patients), diabetes
mellitus (two patients), amnesia, sinusitis. In three patients the
lumbar puncture was carried out to exclude an acute or chronic
inflammation.
Control patients for ALS. The 14 patients in the control
group had the following diagnoses: migraine with aura, episodic
headache and symptomatic epilepsy, transient ischemic attack,
borreliosis, anterior ischemic optic neuropathy (AION), PD,
vestibular neuritis with depression and iron deficiency anemia,
pseudotumor cerebri (PTC), migraine and polymyalgia
rheumatica. For one of the control patients a lumbar puncture
was carried out to exclude an acute or chronic inflammation.
Control patients for CJD. The patients in the control group
had the following diagnoses: migraine, vestibular neuritis, ALS,
vertigo, epilepsy, polyneuropathy, subcortical vascular disease and
ischemia, recessive transient attacks, lower body parkinsonism,
neuritis retrobulbaris and for one case the lumbar puncture was
carried out to exclude an acute or chronic inflammation.
Determination of tau protein
Total tau protein concentrations in CSF samples of the CJD
cohort were measured by a commercially available ELISA
(Innogenetics, Gent, Belgium) [20].
LC-MS/MS analysis of cAMP and cGMP
The CSF samples (35 mL) were mixed with 0.4 M perchloric
acid (1:1) and centrifuged at 200006 g for 10 min at 4uCt o
precipitate and remove proteins. The supernatant was analysed in
duplicate by LC-MS/MS as described previously [27]. The LC-
MS/MS system consisted of an HTS PAL autosampler (CTC
Analytics AG, Zwingen, Switzerland), maintained at 4uC during
all experiments, Agilent 1200 Binary Pump, Agilent 1200 Micro
Vacuum Degasser and Agilent 1200 Thermostatted Column
Compartment (Agilent Technologies, Morges, Switzerland).
Chromatographic separation was carried out at room temperature
using a reversed-phase column (Varian MetaSil AQ, 120-5, C18,
10062.0 mm, Varian, Palo Alto, USA). Mobile phase A consisted
of 0.1% formic acid in water and mobile phase B was 100%
acetonitrile. The following gradient elution profile was applied at a
flow rate of 0.4 mL/min: 0.00 min: 100% A, 0.50 min: 100% A,
1.00 min: 10% A, 2.20 min: 10% A, 2.30 min: 100% A,
3.50 min: 100% A. The column switching valve was set to the
waste at 0.00 min, to the mass spectrometer at 1.50 min and to the
waste again at 2.50 min.
Eluates were detected with an API 4000 triple quadrupole mass
spectrometer (AB Sciex, Ontario, Canada) in the positive
electrospray ionisation (ESI) mode by multiple reaction monitor-
ing (MRM). The following transitions were used: 330.08 R 136.10
(cAMP) and 346.15 R 152.10 (cGMP). The injection volume was
25 mL.
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CSF (aCSF, 147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2,
0.85 mM MgCl2, and 1 mM Na2HPO4, pH 7.0–7.4) and 0.4 M
perchloric acid. The stable isotope-labelled internal standards
13C5-cAMP (transition: 335.15 R 136.20) and
15N5-cGMP
(transition: 351.03 R 157.00) were added to the standard solutions
and CSF samples in a concentration of 100 nM to account for
matrix effects and variations in ionisation.
Stability of cAMP and cGMP in CSF
A CSF sample was divided into 100 mL aliquots and frozen at
280uC to investigate the stability of cAMP and cGMP. Afterwards
the aliquots were either stored at 4uC or at room temperature (RT)
for the indicated time (see Fig. 1). Three aliquots underwent a
series of freeze/thaw cycles that consisted of thawing at RT,
incubating for 5 min at RT and freezing at 280uC.
Statistics
All statistical analyses were carried out with GraphPad Prism
5.03 (La Jolla, USA). The data of the stability measurement were
analysed by a one-way ANOVA and compared with the control
sample by Dunnett’s multiple comparison test. The cAMP and
cGMP concentrations of the different groups of patients were
compared by a Mann-Whitney or Kruskal-Wallis test. Spearman’s
rank correlation coefficient (r) was calculated for cAMP or cGMP
with the Hoehn & Yahr score, MMSE, age (PD and PDD), tau
protein as well as survival (CJD). A p-value,0.05 was regarded as
statistically significant. Cut-off levels of cAMP, cGMP, tau protein
and tau/cAMP for diagnosis of CJD were selected by calculating
the Youden Index of the ROC curves.
Results
cAMP & cGMP are stable in human CSF
Different storage and handling conditions during and after CSF
collection could affect the results. We checked the stability of
cAMP and cGMP in CSF under diverse conditions to reduce the
risk of false positive or negative results.
The concentrations measured in the differently treated CSF samples
were all within the range of 6 1 SD of the control sample (Fig. 1). This
is the intrinsic variation of the LC-MS/MS method. Additionally, we
compared CSF samples taken from control subjects and stored for
several years or collected recently. There was no significant difference
in the mean cAMP and cGMP concentrations (data not shown)
indicating the good stability of cAMP and cGMP.
CSF concentrations of cAMP & cGMP are not different in
PD, PDD and controls
We measured the concentrations of cAMP and cGMP in CSF
samples of patients suffering from PD or PDD and control patients
(CON) (Fig. 2). Mean CSF concentrations of cAMP were
13.20 nM (CON), 13.01 nM (PD) and 15.76 nM (PDD) and of
cGMP 3.15 nM (CON), 5.11 nM (PD) and 3.97 nM (PDD).
There was no statistical significant difference between the groups.
A correlation analysis of the measured CSF concentrations in
PD and PDD patients revealed no correlation between cAMP or
cGMP and the Hoehn & Yahr score (p=0.80 for cAMP, p=0.70
for cGMP), MMSE (p=0.53 for cAMP, p=0.67 for cGMP) or age
(p=0.71 for cAMP, p=0.49 for cGMP).
CSF concentrations of cAMP & cGMP are not different in
ALS and controls
The measurement of the concentrations of cAMP and cGMP in
CSF of ALS and control patients yielded mean values of 10.93 nM
(CON) and 10.81 nM (ALS) for cAMP and 2.00 nM (CON) and
1.64 nM (ALS) for cGMP (Fig. 3). Neither cAMP nor cGMP
concentrations were significantly different between the groups.
CJD patients have lower CSF concentrations of cAMP &
cGMP
The LC-MS/MS analysis of cAMP and cGMP in CSF of
patients with CJD showed a marked reduction of cAMP of about
Table 1. Characteristics of patients included in the study.
Diagnosis Gender (m/f) Age (years) Disease related characteristics
PD study Hoehn & Yahr score MMSE
CON 4/5 55.4618.3 - -
PD 6/5 69.669.0 1.960.7
a 27.466.4
b
PDD 2/6 77.969.0 3.261.4 19.367.5
c
p-value 0.005 0.06 0.04
ALS study First symptoms
CON 5/9 49.0616.8 -
ALS 9/5 61.4611.0 S=8, B=4, S+B=2
p-value 0.06
CJD study PRNP Polymorphism
Codon 129
Tau protein (pg/mL)
CON 6/5 66.4611.8 not done 3006237
CJD 6/9 60.3612.9 MM=8,MV=1,VV=2 not done=4 1018868477
p-value 0.32 0.001
Data are means 6 SD, Data are missing for.
athree,
bsix and.
cone patients.
CON: control patients, m: male, f: female, S: spinal, B: bulbar, S+B: spinal and bulbar, PRNP: prion protein gene, M: methionine, V: valine.
doi:10.1371/journal.pone.0032664.t001
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12.60 nM (CON) and 3.90 nM (CJD). We observed a similar
decrease for cGMP (255%) with mean concentrations of 2.45 nM
(CON) and 1.08 nM (CJD).
Since tau protein is suggested for the diagnosis of CJD we
looked for a correlation with the cyclic nucleotides [20]. Fig. 5
shows a correlation analysis of cAMP and cGMP with tau protein.
There was a weak but significant negative correlation (p=0.04)
between cAMP and tau protein concentrations in the CSF of CJD
patients (Fig. 5A). Concentrations of cGMP did not correlate with
tau protein (Fig. 5B).
We further investigated, whether cAMP and cGMP concentra-
tions correlated with the survival of the CJD patients. The patients
had a survival time of 50.9625.1 d (mean 6 SEM) after lumbar
puncture. There was no correlation with cAMP (p=0.35) or
cGMP (p=0.48).
Suitability of cAMP & cGMP in CSF as diagnostic
biomarkers for CJD
We calculated ROC curves to evaluate the diagnostic suitability
of the cyclic nucleotides in CJD. ROC curves are depicted in Fig. 6
Figure 1. Cyclic AMP and cGMP are stable in human CSF.
Stability of cAMP and cGMP in human CSF after different handling and
storage conditions. A CSF sample was splitted and subjected to the
indicated procedures before being measured by LC-MS/MS in triplicate.
Data were analysed by a one-way ANOVA followed by Dunnett’s
multiple comparison tests to compare the different groups against the
control. Data are means 6 SD, p=0.58 (cAMP), p=0.70 (cGMP).
doi:10.1371/journal.pone.0032664.g001
Figure 2. CSF concentrations of cAMP and cGMP are not
altered in PD and PDD. CSF concentrations of cAMP (A) and cGMP
(B) in cases with Parkinson’s disease (PD, n=11), PD dementia (PDD,
n=8) and control patients (CON, n=9) measured by LC-MS/MS. Data
are means 6 SEM, p=0.50 (cAMP), p=0.57 (cGMP), Kruskal-Wallis test.
doi:10.1371/journal.pone.0032664.g002
Figure 3. CSF concentrations of cAMP and cGMP are not
altered in ALS. CSF concentrations of cAMP (A) and cGMP (B) in cases
with amyotrophic lateral sclerosis (ALS, n=14) and control patients
(CON, n=14) measured by LC-MS/MS. Data are means 6 SEM, p=0.80
(cAMP), p=0.48 (cGMP), Mann-Whitney test.
doi:10.1371/journal.pone.0032664.g003
Figure 4. CSF concentrations of cAMP and cGMP are reduced in
CJD. CSF concentrations of cAMP (A) and cGMP (B) in cases with
Creutzfeldt-Jakob disease (CJD, n=15) and control patients (CON,
n=11) measured by LC-MS/MS. Data are means 6 SEM, **p,0.01,
Mann-Whitney test.
doi:10.1371/journal.pone.0032664.g004
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curve (AUC) are listed in Table 2. The sensitivity and specificity of
cAMP and cGMP increased using the product of the concentra-
tions of cAMP and cGMP.
The ratio of tau/cAMP also resulted in an increase of the AUC.
Cyclic GMP had the same effect (data not shown).
Discussion
In this study, we investigated the concentrations of the cyclic
nucleotides cAMP and cGMP in CSF of patients suffering from
PD, PDD, ALS or CJD in comparison with controls. The
measured values for cAMP and cGMP in the control groups agree
with previously reported data showing concentrations in the range
of 8–14 nM (cAMP) and 2–3 nM (cGMP) [28–33]. For the first
time we observed significantly lower cAMP and cGMP concen-
trations in CJD patients. In PD, PDD and ALS patients no effect
on cAMP and cGMP CSF concentrations was detected.
Both nucleotides cAMP and cGMP are stable in human CSF
during different handling and storage conditions as shown in Fig. 1.
Even the storage of CSF over years did not affect cAMP and
cGMP concentrations in the present study. The high stability of
the cyclic nucleotides in CSF is in agreement with stability
measurements in other biological matrices [34].
The impact of the cyclic nucleotides cAMP and cGMP in CSF
of PD cases has been questioned for several years [28–30,33,35–
37]. Alterations in the central dopaminergic system after
pharmacological modulation are reflected in changes of CSF
concentrations of cAMP and cGMP [38]. Since dopaminergic
neurons in the substantia nigra pars compacta are degenerated in
PD, an alteration of CSF cyclic nucleotides seems conceivable.
However, in the present study we found no differences in the
concentrations of cAMP and cGMP between PD and control
patients. This is in line with the findings by Cramer and colleagues
who firstly addressed this topic [33] and their observation was
confirmed by others [28–30,33,35]. In contrast, two studies
reported reduced cyclic nucleotide concentrations in the CSF of
PD patients [36,37]. A difference in the mean age of the study
populations can be ruled-out as a cause for the discrepancies
because the concentration of cAMP and cGMP are not age
dependent [33]. Drug-induced variations are also unlikely since
most of the patients used in the studies were drug-free at the time
of CSF collection and L-DOPA, the most widely used anti-
parkinsonian drug, does not affect cyclic nucleotides in human
CSF [33,37]. Circadian changes for cAMP do not exist [33]. The
discrepancies between some of the studies may be due to the small
number of patients and the high inter-individual variations of
cAMP and cGMP concentrations.
In contrast to PD, there are no studies of the cyclic nucleotide
concentrations in CSF of PDD patients. Similar to the observation
in PD patients without dementia we did not find differences in
PDD cases. There are reports of alterations in other types of
dementia but the findings are not consistent. The discrepancies
could be ascribed to distinct primary disorders causing the
dementia [39–41]. This indicates that the alterations in CSF
Figure 5. CSF concentrations of cAMP negatively correlate with
tau protein in CJD. Correlation of tau protein with cAMP (A) or cGMP
(B) concentrations in CSF of Creutzfeldt-Jakob disease (CJD) patients.
Spearman’s rank correlation coefficient (r) and the respective p-values
are given.
doi:10.1371/journal.pone.0032664.g005
Figure 6. Diagnostic potency of cAMP and cGMP for CJD.
Receiver operating characteristic (ROC) curves of cAMP, cGMP and tau
protein concentrations in CSF and combinations of them (cAMP6cGMP,
tau/cAMP) for the differentiation of Creutzfeldt-Jakob disease (CJD) and
control patients. Values for the area under the curve (AUC) and the best
combinations of sensitivity and specificity are listed in Table 2.
doi:10.1371/journal.pone.0032664.g006
Table 2. Characteristics of potential CSF biomarkers for CJD
in ROC analysis.
Parameter cAMP cGMP cAMP6cGMP Tau protein
Tau/
cAMP
AUC 0.8606 0.8545 0.9152 0.9758 0.9879
p-value 0.002 0.002 0.001 0.001 0.001
Cut-off
1 ,10.44 nM ,0.96 nM ,5.92 .977 pg/mL .174.7
Sensitivity (%) 100 66.7 80.0 93.3 93.3
Specificity (%) 63.6 100 90.9 100 100
AUC: area under the curve.
1The cut-off was calculated using the Youden index [24].
doi:10.1371/journal.pone.0032664.t002
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regions not responsible for dementia but affected by the primary
disease. Our findings support this hypothesis since the cyclic
nucleotides were not altered in PD patients without dementia as
well.
Two studies investigated CSF cGMP concentrations in ALS
patients so far with conflicting results. Ilzecka (2004) showed a
50% decrease of cGMP in CSF of ALS cases but an earlier study
by Ikeda et al. (1995) observed no difference [30,42]. Our results
confirm the findings of the study by Ikeda and colleagues that CSF
cGMP is not altered in ALS. As discussed by Ilzecka the
discrepancy with Ikedas study could be mediated by inclusion of
patients with vasomotor headache and increased cGMP concen-
trations in their control group [42]. In our study no patients with
vasomotor headache were included in the control group.
Additionally, we examined cAMP concentrations in CSF of ALS
patients because it is not known if there are differences in CSF
cAMP. Similar to cGMP we observed equal concentrations of
cAMP in ALS and control patients. By using a higher number of
ALS patients in future studies it would be possible to investigate
differences in cAMP and cGMP concentrations between spinal
and bulbar onset of ALS as well. Brettschneider and colleagues
showed that the type of disease onset may influence CSF
concentrations of biomarkers [16]. However, our data indicate
that motor neurons which are degenerated in ALS contribute only
marginally or not at all to the CSF pool of cAMP and cGMP.
For the first time we investigated concentrations of cAMP and
cGMP in CSF of Creutzfeldt-Jakob disease patients. Since there is
a substantial degeneration of the whole brain in prion diseases in a
relatively short time-span [43], we asked whether this is reflected
in CSF cAMP and cGMP. In the present study, CJD patients had
about 70% lower cAMP and about 55% lower cGMP concentra-
tions in the CSF than controls. This effect could originate from an
increased clearance or decreased synthesis of the nucleotides.
Because of the profound degeneration of brain tissue, the
decreased synthesis seems to be more likely. There is no
concentration gradient between CSF and blood because they
contain similar concentrations of cAMP and cGMP [44]. This fact
makes an increased diffusion of the cyclic nucleotides into the
blood unlikely that could result from an impairment of the blood-
CSF-barrier in the choroid plexus. An increased release of PDEs
by necrotic cells could also influence the CSF content of cyclic
nucleotides.
In our study, the CJD patients distinguish from PD and ALS
cases by the reduction of cAMP and cGMP concentrations in
CSF. Therefore, we evaluated the suitability of cAMP and cGMP
as biomarkers for CJD. The ROC analysis showed that both cyclic
nucleotides have the potential for a diagnostic marker. With a
sensitivity of 100% and specificity of 63.6% for cAMP and a
sensitivity of 66.7% and specificity of 100% for cGMP they do not
reach the potency of other CJD biomarkers, e.g. tau protein, 14-3-
3 protein or S-100 protein [20,45,46]. We obtained a marked
increase of the diagnostic potency combining both cyclic
nucleotides. With this approach, the sensitivity and specificity
(80.0% and 90.9%, respectively) is in the range of other reported
CJD biomarkers [46,47]. Tau protein featured a better diagnostic
potential than cAMP and cGMP in our study cohort, but the
potency is quite high when being compared with ROC curves of
tau protein in other studies [20,47].
In contrast to cGMP, there is a significant correlation between
tau protein and cAMP concentrations. The combination of tau
with cAMP in a single ratio tau/cAMP again resulted in an
improvement of the diagnostic potency although sensitivity and
specificity where similar. We assume that the potential of the
combination of tau protein and cAMP is underestimated in our
study since the potency of tau protein itself is very high in our
cohort. Using cAMP in this ratio seems to be more useful than
cGMP because of the more pronounced decrease of cAMP in CJD
patients.
Although the diagnostic potency of cAMP and cGMP alone or
in combination is lower than for other recently established
potential biomarkers of CJD such as ERK2 or ubiquitin, there
are still some advantages of the cyclic nucleotides [21,22]. Both
nucleotides are stable in CSF also under different handling and
storage conditions. Especially cAMP could be helpful in the
differential diagnosis of CJD and Alzheimer’s disease (AD) patients
because the currently used biomarkers are lacking specificity.
Dying neurons release tau protein which indeed is elevated in the
CSF of CJD and AD patients. Thus, tau protein is a general
marker for neurodegeneration rather than a disease-related
biomarker. Similarly, there are AD cases that show a positive
result for the 14-3-3 protein test in CSF which is included in the
diagnosis of CJD [9]. So far we did not analyse CSF cAMP levels
of patients suffering from AD. It has been shown that cAMP
increases in the CSF of patients with AD and the cAMP
concentrations positively correlate with CSF tau protein [39]. In
contrast, our study demonstrates decreased cAMP concentrations
in CJD patients and a negative correlation between CSF cAMP
and tau protein. These data indicate that cAMP concentrations in
the CSF may distinguish between CJD and AD patients. In
combination with the very sensitive tau protein determination in
CSF, cAMP could improve the specificity of the current diagnostic
tests. In the clinic, cAMP and cGMP might be used as markers of
disease progression or even as therapy control.
Immunological assays, which are often preferred in the clinic,
are commercially available for the determination of cAMP and
cGMP if LC-MS/MS analysis is not possible. They enable a
simple and fast analysis without involving expensive equipment.
However, Zhang and colleagues (2009) showed the advantage of
LC-MS/MS over enzyme based immuno assays by comparing a
competitive enzyme immunoassay (EIA) for the analysis of cGMP
in plasma samples and a LC-MS/MS assay for the same analytes.
The LC-MS/MS method showed a better precision and accuracy
as well as reduced matrix effects [34]. In our study the LC-MS/
MS method used for the analysis of the cyclic nucleotides features
the convenience of measureing cAMP and cGMP simultaneously
combined with the provided high selectivity of LC-MS/MS.
The combination of cAMP and cGMP or tau protein and
cAMP is a good example for the combination of different markers
to obtain a higher diagnostic potency. This is important since
biomarkers related to the pathological process are not always
available. Hence, ‘‘secondary’’ markers that indicate downstream
effects of the pathological events have to be used. However,
frequently they lack specificity for the disease as described above
for tau protein. Such weaknesses could be solved or reduced by
combinations of biomarkers. In this context, LC-MS/MS analysis
is a beneficial tool as shown in the present study. It allows the
simultaneous measurement of several analytes in a single run.
Conclusion
In conclusion, we showed reduced concentrations of cAMP and
cGMP in CSF of CJD patients but not in PD, PDD or ALS. This
may be owing to the widespread brain atrophy in CJD compared
with the localised neurodegeneration in the other diseases.
Especially in combination, cAMP and cGMP have a diagnostic
potential for CJD. In combination with tau protein, cAMP led to a
further improvement of this marker. Since there are already fast
and reliable immunological assays for cAMP and cGMP available
cAMP and cGMP in CSF of CJD, PD and ALS Patients
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32664the cyclic nucleotides can easily be included into routine analysis
and may improve the diagnosis of CJD if LC-MS/MS is not
applicable. The measurement of cAMP and cGMP CSF
concentrations may be useful to monitor disease progression and
therapy control. Our study also highlighted the advantages of LC-
MS/MS for the combination of different biomarkers.
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